UK-88947 hydrochloride

Cat. No.: HY-129678: FAQs
Data Sheet Handling Instructions

Molarity Calculator

UK-88947 hydrochloride is a protease inhibitor with activity in inhibiting the replication of human immunodeficiency virus HIV-1. UK-88947 hydrochloride can be added to cells before infection to block the early steps of HIV-1 replication. The use of UK-88947 hydrochloride shows its specific inhibitory effect on HIV-1. At the same time, when the virus infects cells, it inhibits the action of viral protease and affects the virus replication process.

For research use only. We do not sell to patients.

UK-88947 hydrochloride Chemical Structure

CAS No. : 137015-76-0

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description	UK-88947 hydrochloride is a protease inhibitor with activity in inhibiting the replication of human immunodeficiency virus HIV-1. UK-88947 hydrochloride can be added to cells before infection to block the early steps of HIV-1 replication. The use of UK-88947 hydrochloride shows its specific inhibitory effect on HIV-1. At the same time, when the virus infects cells, it inhibits the action of viral protease and affects the virus replication process^[1].
Molecular Weight	772.41
Formula	C₄₁H₆₂ClN₅O₇
CAS No.	137015-76-0
SMILES	O=C(O)C[C@@H](C(N[C@@H](CC1=CC=CC=C1)C(O)C[C@H](C(NCCC(C)C)=O)CC(C)C)=O)NC([C@H](CC2=CC=CC=C2)NC(C3(N)CCCCC3)=O)=O.Cl
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (265 KB) Handling Instructions (2659 KB)
References	[1]. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase [Content Brief]